Aleksandra Rizo
Direktor/Vorstandsmitglied bei SYNDAX PHARMACEUTICALS, INC.
Vermögen: - $ am 30.04.2024
Profil
Aleksandra Rizo is currently the President & Chief Executive Officer at Vividion Therapeutics, Inc. and a Director at Syndax Pharmaceuticals, Inc. She previously worked as an Executive Director-Strategy & Clinical Leader at Celgene Corp.
from 2018 to 2019, a Senior Director & Team Leader Compound Development at Janssen Research & Development LLC from 2008 to 2018, and as the Chief Medical Officer & Executive Vice President at Geron Corp.
from 2019 to 2022.
Rizo holds a doctorate degree from the University of Groningen, the University of Tokyo, and Saints Cyril & Methodius University of Skopje.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.05.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Aleksandra Rizo
| Unternehmen | Position | Beginn |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 14.05.2024 |
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Vorstandsvorsitzender | 24.01.2023 |
Ehemalige bekannte Positionen von Aleksandra Rizo
| Unternehmen | Position | Ende |
|---|---|---|
| GERON CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 08.07.2022 |
| CELGENE | Corporate Officer/Principal | 01.01.2019 |
Janssen Research & Development LLC
 Janssen Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Janssen Research & Development LLC is a company that provides research and development medicines and solutions to other medical needs. The company is based in Raritan, NJ. | Corporate Officer/Principal | 01.03.2018 |
Ausbildung von Aleksandra Rizo
| Saints Cyril & Methodius University of Skopje | Doctorate Degree |
| University of Groningen | Doctorate Degree |
| University of Tokyo | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GERON CORPORATION | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Janssen Research & Development LLC
Janssen Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Part of Johnson & Johnson, Janssen Research & Development LLC is a company that provides research and development medicines and solutions to other medical needs. The company is based in Raritan, NJ. | Commercial Services |
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
